AI and Robotics: Automating Immune Cell Manufacturing for Global Access

Revolutionizing Cell Therapy Manufacturing

• 💡 The current production of CAR-T and NK cells is manual and prohibitively expensive, limiting global access to life-saving treatments.
• 🚀 A world-first robotic system leverages machine learning, machine vision, and AI to automate the manufacturing process.
• ✅ This system aims to democratize cell therapy, making it scalable and accessible to a wider population.

Automated Immune Cell Production

• 🔬 The robotic system can take an apheresis blood sample and, within approximately seven days, generate billions of ENK or CT cells.
• ❄️ These manufactured cells can be frozen and stored, creating an "off-the-shelf" supply for patients.
• 🎯 The initiative is envisioned as a "Red Cross of Cancer," providing a global resource for immune-protecting cells.

Global Deployment and Vision

• 🌍 The first robotic systems are planned for deployment in the United States and Riyadh, with a goal of installation before September 2026.
• 🤝 This collaboration between countries aims to change the course of cell therapy by enabling global sharing of this technology.

Addressing Viral Persistence Concerns

• ⚠️ A significant concern is that some antibody vaccines do not clear viruses, leading to viral persistence.
• 🦠 Uncleared viruses can be oncogenic, stimulating inflammation and potentially knocking down P-53, a crucial cancer-preventing protection.
• 🌱 Research is being funded for a long-term trial with an antiviral designed to clear the virus, offering a solution to this concern.